Navigation Links
RTA 402 Shown to Protect Animals Against Toxicities of Standard,Cancer Treatments

effects of the treatment. Consequently, an agent that reduces these toxicities and also has a significant direct anti-cancer effect would likely gain rapid acceptance in a variety of first-line and second-line treatment settings.

RTA 402 has recently begun Phase 2 clinical studies in cancer patients. An ongoing Phase 1 study in cancer patients has indicated that RTA 402 has potent single-agent anti-cancer activity in patients with several different types of tumors, is well tolerated with only mild, transient side effects, and suppresses its target proteins NF-kB and STAT3 in human tumors. A Phase 1/2 study of RTA 402 in combination with gemcitabine is underway in patients with pancreatic cancer. Analogues of RTA 402 are in advanced preclinical development for cancer, anti-inflammatory, and neurodegenerative indications.

About Reata

Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on selecting and discovering promising early drug development opportunities and translating them into successful marketed drugs that target major unmet clinical needs in cancer, inflammation and neurodegenerative disease. The company's two lead programs are entering advanced clinical trials for deadly, late-stage cancers. In parallel with its clinical development, Reata is advancing a breakthrough drug discovery platform using protein misfolding, identified as a key factor in cancer and neurodegenerative disease, to feed its pipeline of small molecule therapeutic candidates. Reata takes a new and different approach to biotechnology, managing its pipeline as a portfolio of opportunities that can be advanced on a single management and physical infrastructure, streamlining the route to human trials and approval. Founded in 2002, Reata is based in the Dallas area. For more information, visit www.reatapharma.com

Contact

Media:
For Reata Pharmaceuticals, Inc.
Kathryn Morris, 845-635-9828
'"/>




Page: 1 2 3

Related medicine technology :

1. Gabapentin Shown Effective for Fibromyalgia Pain
2. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
3. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
4. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
5. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
6. RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds Significant Promise for Treating Breast Cancer
7. Accelreon Pharmas ACE-031Shown to Increase Muscle Mass in Preclinical Studies
8. Cethromycin Shown Effective Against Anthrax in Study
9. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
10. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
11. Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show
Post Your Comments:
(Date:10/9/2008)...rstCall/ -- Diamyd Medical reports,that the world,...d Journal,of Medicine, has published an article wi...R) diabetes vaccine for type 1 diabetes., (Logo: ...94 ), The article is now available on the journa...n print on October 30. It presents the,results of ...
(Date:10/8/2008)...ntinued and Headcount to be Reduced, Summary: Genm...Zanolimumab Program to be Discontinued and the Co... Employees, COPENHAGEN, October 8 /PRN...ced today that it is discontinuing development of ...lt of a portfolio review and,assessment of the org...
(Date:10/8/2008)... improvement in patients with pulmonary arter...tions have limited benefit for this debilitating, ...l disease, -- Imatinib mesylate, available as G...nown to inhibit protein associated with PAH, -- ... mesylate in PAH in 2009 EAST HANOVER, N.J.,...
(Date:10/7/2008)... the Osteoarthritis Research Society,International.../- Ferring Pharmaceuticals Inc.,recen...oarthritis of the,Knee, showing that EUFLEXXA(R) (...gh molecular weight form of intra-articular hyalur...saline (IA-saline) for the relief,of pain in knee ...
Breaking Medicine Technology:Diamyd(R) Study Published in Prestigious New England Journal of Medicine 2Diamyd(R) Study Published in Prestigious New England Journal of Medicine 3Diamyd(R) Study Published in Prestigious New England Journal of Medicine 4Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 2Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 3Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 5Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 6Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 7Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 8Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 9Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 10Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 11Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 12Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 1KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 2KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 3KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 4KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 5KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 6KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 7KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 8KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 9KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 10KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 11KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 12KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 13KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 14AMA Foundation Presents 2410 000 Scholarships to Promising Medical Students 25298 1AMA Foundation Presents 2410 000 Scholarships to Promising Medical Students 25298 2AUDIO from Medialink and Pfizer 3A Community Health Centers Celebrated for Making Quality Care Available to Uninsured Americans 25295 1VirtualScopics Receives NASDAQ Delisting Notice 3B Company Files Appeal to Stay Delisting 25290 1VirtualScopics Receives NASDAQ Delisting Notice 3B Company Files Appeal to Stay Delisting 25290 2VirtualScopics Receives NASDAQ Delisting Notice 3B Company Files Appeal to Stay Delisting 25290 3
...)--Jun 13, 2007 - EPIX,Pharmaceuticals, Inc. (NASD... 3 trial of PRX-00023, a novel long-acting 5-HT1A ...the 47th Annual New,Clinical Drug Evaluation Unit ...g is sponsored by the National Institutes of,Healt...acology., The presentation highlighted data from a...
...WIRE)--Jun 14, 2007 - Can-Fite,BioPharma (TASE:CFB... Stock Exchange Exchange, proceeds with the develo... to CF101, which is currently,in clinical trials a...kend Can-Fite will present at the EUALR annual con...esults showing effective,anti-inflammatory activit...
Other Medicine Technology:EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 2EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 3EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 4Can-Fite Proceeds with Development of Third Drug; Progress in,Development of CF502 Will Be Presented at the Annual European,Congress of Rheumatology 2
(Date:10/10/2008)... BEDFORD, Mass., Oct. 10 /PRNewswire-FirstCall/...loper, manufacturer and supplier of premium,diagno...ts dedicated to,serving the healthcare needs of wo...uarter and fiscal 2008 operating results on Tuesda...ction with the release, management will,host a con...
(Date:10/10/2008)... PARK CITY, Utah, Oct. 10 /PRNewswire/ -- NuVie... management of Trace Life Sciences Inc.,(Trace), i...cyclotron,production facilities in Denton, Texas. ... Indium-111, Iodine-123 and Thallium-201 used in,m... NuView Chairman and,CEO, stated that "We are conf...
(Date:10/10/2008)... Coach Holly Warlick Teams Up with Legal and Me...rst-Ever Cancer and Careers Seminar in,Knoxville, ...gnition of National,Breast Cancer Awareness Month,... have joined forces with YWCA Knoxville, The Welln...ocate Holly Warlick, University of Tennessee,women...
(Date:10/10/2008)... The Healthcare Technolog...Care , Exton, PA (PRWEB) ...Valley Chapters of the national Healthcare Informa...ned forces to bring regional health information te...onal conference entitled The Healthcare Technology...
Breaking Medicine News(10 mins):Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2
...f that only bad dogs bite, it has been found that ... argue pediatricians//. Doesn’t sound alarming? Ac...erican Academy of Paediatrics (AAP), dogs bite nea... More than half of all these victims are younger t...
...awaharlal Institute of Post-graduate Medical Educa... chain agitation’// to protest the move to reserve...ons. Students of the Central government-administe...ally inside the Institute's premises before organi...
...vegan women's levels of IGF are lower than those o...twin production is higher in countries that consum... Haggerty who studies nutrition, fertility and dis... Aberdeen, UK, was quoted by Nature as saying. Bu...
...Nadu and their support groups have planned to orga...e UN towards non-implementation// of the recommend...(UNGASS) to address the problem of HIV/AIDS. Esth...f ActionAid, told reporters here that UNGASS in 20...
Other Medicine News:Health News:Watch Out! Even Good Dogs Can Bite Your Kids 2
Flattened Blunt Tip, Angled; 13mm from angle to tip; 3mm "U" shape tip; overall length excluding hub 28mm; in stainless steel.
Set of Five, Long, with side port; all approximately 75mm in length; in Stainless Steel.
HYDRACLEAR is our brandname for a remarkable moisture rich element that lies throughout the interior and exterior of the ACUVUE ADVANCE Brand Contact Lenses creating a unique soft, silky feel.
The only solution for in-line digital measurement
Medicine Products: